Sort   by:  
 Page size 
UnknownCerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals.
Not available
S-EPMC4119225 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownThe genetic architecture of the human cerebral cortex.
Not available
S-EPMC7295264 | biostudies-literature
UnknownDeterminants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls.
Not available
S-EPMC10145209 | biostudies-literature
UnknownThe impact of viral mutations on recognition by SARS-CoV-2 specific T cells.
Not available
S-EPMC8552693 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
UnknownEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607 | biostudies-literature
UnknownSeverity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.
Not available
S-EPMC4309077 | biostudies-literature
Sort   by:  
 Page size